Open AccessLong-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial
Author(s) -
Dinesh Khanna,
Celia J F Lin,
Daniel E. Fürst,
Bridget K. Wagner,
Mauro Zucchetto,
Ganesh Raghu,
Fernando J. Martínez,
Jonathan G. Goldin,
Jeffrey Siegel,
Christopher P. Denton
Publication year - 2022
Publication title -
american journal of respiratory and critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.272
H-Index - 374
eISSN - 1535-4970
pISSN - 1073-449X
DOI - 10.1164/rccm.202103-0714oc
Subject(s) - tocilizumab , medicine , placebo , interstitial lung disease , adverse effect , gastroenterology , clinical endpoint , randomized controlled trial , surgery , lung , pathology , disease , alternative medicine